title: Chronic sulforaphane oral treatment accentuates blood glucose impairment and may affect GLUT3 expression in the cerebral cortex and hypothalamus of rats fed with a highly palatable diet.
abstract: Obesity and insulin resistance are the key factors underlying the etiology of major health problems such as hypertension, diabetes and stroke. These important health issues lead researchers to investigate new approaches to prevent and treat obesity and insulin resistance. Good candidates are the phytochemical compounds that have been extensively studied in the field. Therefore, the aim of this study was to test whether sulforaphane (SFN, 1 mg kg⁻¹, 4 months treatment), a potent inducer of antioxidant enzymes present in cruciferous vegetables, had some beneficial effects on obesity and insulin resistance induced by a highly palatable (HP) diet in male Wistar rats. Glucose tolerance, serum and hepatic lipid levels, lipid profile, ALT, AST, urea and creatinine, GLUT1 and GLUT3 levels in the cerebral cortex, hippocampus and hypothalamus were analyzed. Glucose tolerance was lower in the HP diet groups, especially in the HP group treated with SFN. Except for the liver triacylglycerols, no differences were found in serum lipids, hepatic and kidney markers of the HP diet groups. Although expression of GLUT1 was similar between groups for all three brain structures analyzed, expression of GLUT3 in the cortex and hypothalamus had a tendency to decrease in the HP diet group treated with SFN. In conclusion, SFN at the specific dose was able to accentuate glucose intolerance and may affect GLUT3 expression in the cerebral cortex and hypothalamus.
authors.affiliation: Department of Biochemistry, ICBS, Universidade Federal do Rio Grande do Sul- UFRGS, Rua Ramiro Barcelos, 2600 Anexo, CEP 90035003, Porto Alegre, RS, Brazil. carolguerini@hotmail.com
authors.forename: C G
authors.initials: CG
authors.lastname: Souza
authors.forename: B P
authors.initials: BP
authors.lastname: Riboldi
authors.forename: F
authors.initials: F
authors.lastname: Hansen
authors.forename: J D
authors.initials: JD
authors.lastname: Moreira
authors.forename: D G
authors.initials: DG
authors.lastname: Souza
authors.forename: A M
authors.initials: AM
authors.lastname: de Assis
authors.forename: L M
authors.initials: LM
authors.lastname: Brum
authors.forename: M L S
authors.initials: ML
authors.lastname: Perry
authors.forename: D O
authors.initials: DO
authors.lastname: Souza
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D051274:Glucose Transporter Type 3 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007333:Insulin Resistance; D017879:Isothiocyanates / Q000008:administration & dosage*; D008297:Male; D009765:Obesity / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013454:Sulfoxides
chemical_list: D001786:Blood Glucose; D051274:Glucose Transporter Type 3; D017879:Isothiocyanates; C495690:Slc2a3 protein, rat; D013454:Sulfoxides; C016766:sulforaphane